Merus
Merus N.V. is a Dutch clinical-stage immuno-oncology company developing bispecific and trispecific antibody therapeutics through its proprietary Multiclonics® platform, serving cancer patients with lead assets including the FDA-approved BIZENGRI® and Phase 3 candidate petosemtamab. Acquired by Genmab for ~$8 billion in December 2025.
- Company typePrivate
- Founded2003
- HeadquartersUtrecht, Netherlands
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merus does
Merus N.V. was a Dutch clinical-stage immuno-oncology company founded in 2003 and headquartered in Utrecht, the Netherlands, with a U.S. subsidiary in Cambridge, Massachusetts. The company developed multispecific antibody therapeutics for cancer using its proprietary Multiclonics® platform, which comprises three modular formats — Biclonics® for bispecific antibodies, Triclonics® for trispecific antibodies, and ADClonics® for bispecific antibody-drug conjugates. These formats enable high-yield manufacturing in a standard IgG architecture without linkers or fusion proteins, with candidate identification driven by high-throughput functional screening.
The company's pipeline included the FDA-approved BIZENGRI® (zenocutuzumab-zbco), a HER2×HER3 bispecific approved in December 2024 under accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma; the lead clinical asset petosemtamab (MCLA-158), an EGFR×LGR5 bispecific in Phase 3 trials for head and neck squamous cell carcinoma and being evaluated in metastatic colorectal cancer; and earlier-stage candidates MCLA-129 (EGFR×c-MET), MCLA-145 (CD137×PD-L1), and MCLA-117 (CLEC12A×CD3 T-cell engager).
Merus operated a partnership-driven business model, generating revenue from upfront payments, development and commercial milestones, and royalties from collaborators including Incyte (up to 11 programs), Eli Lilly (CD3 bispecifics), Gilead (Triclonics®, up to $1.5 billion potential), Biohaven (ADCs), Betta Pharmaceuticals (China), and Ono Pharmaceutical (Japan). U.S. commercialization of BIZENGRI was licensed exclusively to Partner Therapeutics. The company was acquired by Genmab A/S for approximately $8 billion in an all-cash transaction completed on December 30, 2025, after which Merus delisted from Nasdaq and became a wholly-owned subsidiary with Genmab executives assuming its leadership.
Merus firmographics
Firmographics- Name
- Merus
- Legal name
- Merus N.V.
- Website
- https://merus.nl
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Merus N.V. is a Dutch clinical-stage immuno-oncology company developing bispecific and trispecific antibody therapeutics through its proprietary Multiclonics® platform, serving cancer patients with lead assets including the FDA-approved BIZENGRI® and Phase 3 candidate petosemtamab. Acquired by Genmab for ~$8 billion in December 2025.
- Ownership category
- akta.pro rank
Merus industry classification
Industry- Product category
- Bispecific Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Merus is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Merus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Collaboration and Licensing Revenue: Merus generates revenue through strategic collaborations with pharmaceutical companies including upfront payments, milestone payments (development and commercialization), and tiered royalty payments on product sales. Key partners include Incyte (up to 11 programs), Eli Lilly (CD3 bispecifics), Gilead (Triclonics®, up to $1.5B potential), Biohaven (ADCs), and regional partners Betta Pharmaceuticals and Ono Pharmaceutical.
- Product Sales (BIZENGRI): Following FDA accelerated approval of BIZENGRI (zenocutuzumab-zbco) in December 2024 for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, Merus receives product revenue through its licensing agreement with Partner Therapeutics for U.S. commercialization.
- Public Equity Offerings: The company has historically raised capital through public offerings of common shares. Prior to acquisition by Genmab, Merus conducted multiple offerings: $400.2M (May 2024), $150M (August 2023), $300M (June 2025), and $110M (November 2021).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | BIZENGRI patient assistance program |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Merus product offering
Product offeringCore offering
Merus discovers and develops multispecific antibody therapeutics (bispecific and trispecific) for cancer treatment using its proprietary Multiclonics platform (Biclonics, Triclonics, ADClonics). The company has one FDA-approved product, BIZENGRI (zenocutuzumab-zbco), for NRG1 fusion-positive cancers, and a pipeline of clinical-stage candidates led by petosemtamab for head and neck cancer.
Product overview
Merus is a clinical-stage immuno-oncology company developing multispecific antibody therapeutics. The company operates two proprietary technology platforms (Biclonics® for bispecific and Triclonics® for trispecific antibodies) and a related ADClonics® antibody-drug conjugate platform. The marketed product BIZENGRI® (zenocutuzumab-zbco) received FDA accelerated approval in December 2024 for NRG1 fusion-positive cancers. The lead clinical candidate is petosemtamab (MCLA-158), an EGFR×LGR5 bispecific antibody in Phase III trials for head and neck cancer. Additional pipeline candidates include MCLA-129 (EGFR×c-MET), MCLA-145 (CD137×PD-L1), and MCLA-117 (CLEC12A×CD3 T-cell engager). Merus was acquired by Genmab in December 2025 for approximately $8 billion.
Differentiator
Problem solved
Functional benefit
Products and services
- BIZENGRI (zenocutuzumab-zbco) FDA-approved bispecific antibody targeting HER2 and HER3 for treatment of adults with advanced unresectable or metastatic NRG1 fusion-positive pancreatic adenocarcinoma or non-small cell lung cancer. Approved under accelerated approval based on response rate and duration of response.
- Petosemtamab (MCLA-158) Lead bispecific antibody therapeutic candidate targeting EGFR and LGR5 in Phase 3 registrational trials for head and neck squamous cell carcinoma (HNSCC) and being evaluated in metastatic colorectal cancer. Showing single agent clinical activity in previously treated recurrent/metastatic head and neck cancer and in combination with pembrolizumab in first-line PD-L1+ head and neck cancer. Received FDA Breakthrough Therapy Designation.
- MCLA-129 Bispecific antibody targeting EGFR and c-MET in clinical development for non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations and head and neck squamous cell carcinoma. Also being evaluated in combination with osimertinib.
- MCLA-145 Bispecific antibody targeting CD137 and PD-L1 in Phase 1 clinical study for solid tumors, as monotherapy or in combination with pembrolizumab.
- MCLA-117 Bispecific T-cell engager targeting CLEC12A and CD3 in clinical development for acute myelogenous leukemia (AML).
- Biclonics Platform Proprietary bispecific antibody technology platform that generates diverse panels of antibodies and enables functional screening at high throughput to discover therapeutic candidates with unique properties. Does not require linkers or modifications to force correct pairing of heavy and light chains. Licensed to pharmaceutical partners for collaborative drug discovery and development.
- Triclonics Platform Proprietary trispecific antibody technology platform capable of simultaneously binding three targets. Has potential to enable tumor cell-killing activity and/or modulate the immune system for more robust anti-tumor immune responses. Licensed to Gilead Sciences for T-cell engaging multi-specific antibody products.
- ADClonics Platform Antibody-drug conjugate platform utilizing the Biclonics format with a range of linkers and payloads to generate ADCs capable of binding two different targets for improved binding selectivity, internalization, and cancer cell killing activity. Co-developed with Biohaven Pharmaceutical for three novel bispecific ADCs.
Quantifiable outcome
- 100% response rate in first-line left-sided metastatic colorectal cancer patients in Phase 2 trial of petosemtamab monotherapy
- +2 more outcomes
Companies that use Merus
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Merus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Merus partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and regional.
- Halozyme TherapeuticscoreGlobal non-exclusive collaboration and license agreement to develop a subcutaneous formulation of petosemtamab using Halozyme's ENHANZE drug delivery technology. Merus makes upfront payment plus potential milestone payments tied to commercial and sales attainment. Halozyme receives low-mid single digit royalties on net sales.
- Biohaven PharmaceuticalcoreCollaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' Biclonics technology platform and Biohaven's next-generation ADC conjugation and payload platform technologies.
- Gilead SciencesflagshipCollaboration, option and license agreement to use Merus' Triclonics platform to develop T-cell engaging multi-specific antibody products in oncology. Gilead paid $56 million upfront and $25 million equity investment. Potential up to $1.5 billion across three programs plus royalties. Merus can opt for 50/50 profit/loss split on third program.
- Eli Lilly and CompanycoreResearch collaboration and exclusive license agreement leveraging Merus' Biclonics platform to research and develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies. Merus leads discovery and early-stage research funded by Lilly, which is responsible for further development and commercialization.
- Betta PharmaceuticalsregionalStrategic collaboration to develop and commercialize Merus' Biclonics MCLA-129 in China. Betta Pharmaceuticals is responsible for clinical development and potential commercialization in China, while Merus retains full ex-China rights.
- Incyte CorporationcoreGlobal strategic collaboration focused on research, discovery and development of bispecific antibodies utilizing Merus' proprietary Biclonics technology platform. Incyte received exclusive rights for up to eleven bispecific or monospecific antibody research programs.
- Ono PharmaceuticalregionalResearch and license agreement to jointly develop bispecific antibody therapies for undisclosed targets. Ono received worldwide exclusive rights to develop, manufacture, and commercialize resulting products. Merus received upfront payment and is eligible for milestones and sales royalties. Extended in March 2018 for additional bispecific antibody.
- Partner TherapeuticsflagshipPartner Therapeutics has exclusive license for commercialization of BIZENGRI (zenocutuzumab-zbco) in the U.S. market. PTx Assist program provides patient access and insurance support at 1-877-353-8546.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Merus competitors and assessment
Company assessmentBroad incumbents
- Genmab: Genmab A/S is a Danish antibody therapeutics company that acquired Merus in December 2025; it developed and commercializes epcoritamab (Epkinly) with AbbVie and Darzalex with Janssen, making it both the parent company and the most directly comparable antibody-engineering platform company to Merus.
- Roche: Roche has commercialized multiple bispecific antibodies including mosunetuzumab (Lunsumio) and glofitamab (Columvi) in B-cell lymphomas, positioning it as a broad incumbent with overlapping bispecific antibody franchise capabilities to Merus.
- AbbVie: AbbVie co-develops and commercializes epcoritamab (Epkinly) with Genmab in hematologic malignancies, representing a broad incumbent peer with significant bispecific antibody commercial presence overlapping Merus' oncology pipeline.
- Regeneron: Regeneron has developed bispecific antibodies including linvoseltamab (BCMAxCD3) and odronextamab (CD20xCD3), and through Regeneron Bioventures invested in bispecific antibody discovery — overlapping oncology focus with Merus' lead clinical assets.
- AstraZeneca: AstraZeneca has multiple bispecific antibody programs in oncology, including those developed through its Alexion and AstraZeneca oncology franchises, and is a significant antibody therapeutics player whose pipeline overlaps with Merus' oncology focus.
Direct peers
- MacroGenics: MacroGenics develops bispecific antibodies using its proprietary DART and TRIDENT platforms for cancer immunotherapy, with clinical assets targeting HER2, PD-1, and immune checkpoints — directly comparable to Merus' Biclonics bispecific pipeline.
- Zymeworks: Zymeworks develops multispecific antibody therapeutics using its Azymetric and EFECT platforms, including bispecific antibodies in oncology indications — overlapping technology approach and therapeutic focus with Merus' Multiclonics platform.
- Xencor: Xencor engineers bispecific and multispecific antibodies using its XmAb platform, with clinical assets in oncology and autoimmune disease — a direct technology and therapeutic area peer to Merus' bispecific antibody discovery capabilities.
- Akeso: Akeso is a Chinese biotech that has emerged as a leader in bispecific antibodies, most notably with ivonescimab (PD-1xVEGF) for NSCLC — a direct therapeutic and modality competitor to Merus' EGFRxLGR5 and other bispecific oncology assets.
Others
- Eli Lilly: Eli Lilly is both a Merus collaboration partner (CD3 bispecific T-cell engagers using Biclonics platform) and a broader biopharma peer; it advances its own bispecific antibody portfolio (including through Loxo@Lilly) and provides a relevant comparator for licensing economics and large-pharma platform partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Merus social profiles
Digital presenceMerus compliance and trust
Trust signalCompliance3 records
Merus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merus leadership team
Management profileNumber of profiles
Profiles4 records
Merus subsidiaries and ownership
Company hierarchySubsidiaries1 record
Merus funding detail
Funding detailFunding overview
Funding rounds12 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merus
What does Merus do?
Merus discovers and develops multispecific antibody therapeutics (bispecific and trispecific) for cancer treatment using its proprietary Multiclonics platform (Biclonics, Triclonics, ADClonics). The company has one FDA-approved product, BIZENGRI (zenocutuzumab-zbco), for NRG1 fusion-positive cancers, and a pipeline of clinical-stage candidates led by petosemtamab for head and neck cancer.
Is Merus a public or private company?
Merus is a private company. It is classified as corporate owned and is currently acquired.
When was Merus founded?
Merus was founded in 2003. It employs 251 to 500 people.
Where is Merus based?
Merus is headquartered in Utrecht, Netherlands, in the Europe region.
How does Merus make money?
Three revenue lines are on record. Collaboration and Licensing Revenue is the primary driver. The others are product Sales (BIZENGRI) and public Equity Offerings.
Who are Merus's main competitors?
Broad incumbents on record are Genmab, Roche, AbbVie, Regeneron and AstraZeneca. Direct peers are MacroGenics, Zymeworks, Xencor and Akeso. Eli Lilly is listed as an others.
Does Merus have an API?
No public API is recorded for Merus.
What industry is Merus in?
Merus's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.